Magic mushrooms should be used to treat mental health problems, psychiatrist says

Magic mushrooms should be used to treat mental health problems, psychiatrist says

Leading psychiatrist calls for lifting of bars on LSD and magic mushrooms so they can be used in clinical trials to treat common mental health problems

Magic Mushroom  Psilocybe semilanceata also known as Liberty Cap mushrooms, growing in Hampshire Photo AlamyMagic Mushroom (Psilocybe semilanceata) also known as ‘Liberty Cap’ mushrooms, growing in Hampshire Photo: Alamy

 28th  May, 2015

Magic mushrooms and LSD should be legally reclassified so they can be used to treat common mental health problems, a leading psychiatrist has said.

James Rucker, honorary lecturer at the Institute of Psychiatry, said legal restrictions should be lifted on psychedelic drugs, which could provide an effective treatment for anxiety and addictions.

Writing in the BMJ, he said legal restrictions imposed on the medical use of psychedelic drugs, such as LSD and psilocybin, the compound found in “magic” mushrooms, make medical research into their benefits almost impossible.

Dr Rucker said the drugs “were extensively used and researched in clinical psychiatry” in the 1950s and 1960s, with trials suggesting they could provide “beneficial change in many psychiatric disorders”.

French bread spiked with LSD in CIA experiment

However, research ended after 1967, when the drugs were prohibited, and legally classified as schedule 1 class A drugs – that is, as having “no accepted medical use and the greatest potential for harm, despite the research evidence to the contrary”.

As a result, the drugs are more legally restricted than heroin and cocaine.

In his opinion piece, Prof Rucker says: “No evidence indicates that psychedelic drugs are habit forming; little evidence indicates that they are harmful in controlled settings; and much historical evidence shows that they could have use in common psychiatric disorders.”

In fact, recent studies indicate that psychedelics have “clinical efficacy in anxiety associated with advanced cancer, obsessive compulsive disorder, tobacco and alcohol addiction, and cluster headaches,” he suggests.

The classification makes it almost impossible to carry out studies on the drugs, he says, with licenses too expensive for most institutions to afford.

In the UK, to hold a schedule 1 drug, institutions require a license, which costs about £5,000.

Only four hospitals currently hold such licenses, which come with regular police or home office inspections and onerous rules on storage and transport.

Dr Rucker said the rules mean that clinical research involving psychedelics costs at least five times as much as studies involving drugs such as heroin, which are more harmful, yet less restricted.


Credit: Telegraph newspaper

Leave a Reply

Your email address will not be published.